We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OptiBiotix obtains BRC accreditation

5 Jan 2022 07:00

RNS Number : 4249X
OptiBiotix Health PLC
05 January 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSUFWLEESEFF
Date   Source Headline
24th Aug 20177:00 amRNSUS product launch of LPLDL® at trade show
22nd Aug 20177:00 amRNSGlobal manufacturing & supply agreement with Sacco
31st Jul 20174:27 pmRNSTotal Voting Rights
26th Jul 20177:00 amRNSMarket launch for LPLDL® capsules in Germany
17th Jul 20177:00 amRNSSupply agreement with Pharmabiota Ltd
11th Jul 20177:00 amRNSSweetBiotix® development: Results of taste study
6th Jul 20177:00 amRNSGrant of Options
15th Jun 201712:30 pmRNSResult of AGM
15th Jun 20177:00 amRNSSupply agreement with HLH Biopharma GmbH
31st May 20177:00 amRNSHolding(s) in Company
16th May 20177:00 amRNSSuccessful launch of LPLDL and SlimBiome products
9th May 20177:00 amRNSLPLDL® Non-Exclusive European License Agreement
3rd May 20177:00 amRNSPresentation of abstract at conference
25th Apr 20178:50 amRNSFirst German sales
25th Apr 20177:00 amRNSFinal Results
4th Apr 20177:00 amRNSNotice of Results
29th Mar 201710:47 amRNSUK Investor Show attendance
24th Mar 20175:35 pmRNSHolding(s) in Company
21st Mar 201712:00 pmRNSIntention to float SkinBiotherapeutics
15th Mar 20177:00 amRNSConfirmation of Director appointments to the Board
8th Mar 20177:00 amRNSEuropean agreement with Sacco Srl
1st Mar 20177:00 amRNSLaunch of products at Vitafoods 2017
8th Feb 20179:30 amRNSExercise of Warrants and Issue of Equity
26th Jan 20172:06 pmRNSResult of General Meeting
24th Jan 20177:00 amRNSPresentation of research data
18th Jan 20177:00 amRNSAppointment of Sales and Marketing Director
17th Jan 20174:50 pmRNSHolding(s) in Company
13th Jan 20173:44 pmRNSExercise of Option and Issue of Equity
12th Jan 20177:00 amRNSPresentation of research data at ProBiota 2017
11th Jan 201710:04 amRNSExercise of Warrants and Issue of Equity
5th Jan 20177:00 amRNSAppointment of Commercial Director
3rd Jan 20177:00 amRNSIncreased investment in THWLC
23rd Dec 20167:00 amRNSNotice of General Meeting of Warrant Holders
13th Dec 20167:00 amRNSJoint Product Agreement with multinational
1st Dec 20167:00 amRNSExercise of Warrants and Issue of Equity
29th Nov 20167:00 amRNSScientific and Commercial Update
3rd Nov 20167:00 amRNSPresentation of data at European Microbiome Summit
26th Oct 20167:00 amRNSScientific and commerical update
20th Oct 20167:00 amRNSIncreased investment in SkinBiotix Ltd
5th Oct 20167:00 amRNSAppointment of a Chairman for SkinBiotix
28th Sep 20167:00 amRNSChange of Adviser
23rd Sep 20168:29 amRNSExercise of Warrants and Issue of Equity
14th Sep 20164:38 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSConsumer survey results of GoFigure products
25th Aug 20167:00 amRNSHalf-year Report
12th Aug 20163:11 pmRNSExercise of Warrants and Issue of Equity
9th Aug 20167:00 amRNSFirst products in Whole Foods Market Inc
3rd Aug 20167:00 amRNSNotice of Results
2nd Aug 20167:00 amRNSAppointment of Director of Business Development
28th Jul 20162:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.